Mead Johnson seeks U.S. turnaround
This article was originally published in The Tan Sheet
The nutritionals company relies on product launches and rebranding, along with packaging innovations, to reclaim market share in the U.S. from Abbott Nutrition. Net sales in North America and Europe during Mead Johnson's third quarter plummeted 16.5 percent to $286 million. The Glenview, Ill.-based company is introducing products in the U.S. at a record rate to compete with recent Abbott launches, "and we are beginning to see signs of stabilization," said CEO Stephen Golsby during an Oct. 22 earnings call. The firm's Asia/Latin America segment grew 4.9 percent with $413.8 million in net sales during the July-September period. Mead Johnson plans to expand distribution in China and establish a pediatric nutrition institute there, Golsby said. Abbott is developing a similar facility in Singapore (1"The Tan Sheet" March 2, 2009, In Brief). Additionally, Golsby said Mead Johnson has hired Tim Brown, formergeneral manager of Procter & Gamble's North America Personal Health Division, as general manager of its U.S. business
You may also be interested in...
The Abbott Park, Ill.-based health care company completes its acquisition of Advanced Medical Optics - now Abbott Medical Optics - which is No. 3 in the contact lens care market, Abbott says Feb. 26. The European Commission gave the merger final clearance Feb. 20, Abbott says. Santa Ana, Calif.-based AMO reported net sales of $285.2 million, a drop of 6.4 percent, in its final independent fiscal quarter (1"The Tan Sheet" Feb. 23, 2009, In Brief). ... Similac in Singapore: Abbott opens its $300 million nutritional manufacturing facility, its single largest investment in Asia to date. Abbott says Feb. 26 it built the facility in response to increased demand for Similac and other pediatric nutritionals. The facility can serve up to 1 million Asian children annually (2"The Tan Sheet" April 24, 2006, p. 10). Abbott also plans to base a nutrition science research and development center in Singapore, the firm says
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.